Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study

BMC Cancer

Research Article

Lore Decoster¹  Ivan Bautmans²  Louis Nuvagah Forti²  Rose Njemini²  Oscar Okwudiri Onyema²  Tony Mets³  Marc De Waele⁴ 

[1] Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel & Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090, Brussel, Belgium;Gerontology Department and Frailty in Aging Research (FRIA) Group, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090, Brussel, Belgium;Gerontology Department and Frailty in Aging Research (FRIA) Group, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090, Brussel, Belgium;Department of Geriatrics, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, B-1090, Brussel, Belgium;Laboratory of Hematology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, B-1090, Brussel, Belgium;

关键词: Cellular senescence;    Immunosenescence;    Lung cancer;    Chemotherapy;    Immune risk profile;   

DOI  :  10.1186/s12885-015-2013-3

 received in 2014-10-19, accepted in 2015-12-15,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundShifts in CD8+ T-cell subsets that are hallmarks of immunosenescence are observed in ageing and in conditions of chronic immune stimulation. Presently, there is limited documentation of such changes in lung cancer and other malignancies affecting the lungs.MethodsChanges in CD8+ T-cell subsets, based on the expression of CD28 and CD57, were analysed in patients with various forms of cancer affecting the lungs, undergoing chemotherapy and in a control group over six months, using multi-colour flow cytometry.ResultsThe differences between patients and controls, and the changes in the frequency of CD8+ T-cell subpopulations among lung cancer patients corresponded to those seen in immunosenescence: lower CD8-/CD8+ ratio, lower proportions of CD28+CD57- cells consisting of naïve and central memory cells, and higher proportions of senescent-enriched CD28-CD57+ cells among the lung cancer patients, with the stage IV lung cancer patients showing the most pronounced changes. Also observed was a tendency of chemotherapy to induce the formation of CD28+CD57+ cells, which, in line with the capacity of chemotherapy to induce the formation of senescent cells, might provide more evidence supporting CD28+CD57+ cells as senescent cells.ConclusionImmunosenescence was present before the start of the treatment; it appeared to be pronounced in patients with advanced cases of malignancies affecting the lungs, and might not be averted by chemotherapy.

【 授权许可】

CC BY   
© Onyema et al. 2015